Neurocrine Biosciences
NBIX
#1452
Rank
S$18.97 B
Marketcap
S$186.66
Share price
-0.19%
Change (1 day)
0.22%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): S$9.08

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is S$9.01. In 2025 the company made an earnings per share (EPS) of S$6.16 an increase over its 2024 EPS that were of S$4.32.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$9.0847.46%
2025S$6.1642.6%
2024S$4.3233.07%
2023S$3.2557.76%
2022S$2.0669.47%
2021S$1.21-78.21%
2020S$5.57990%
2019S$0.5181.82%
2018S$0.28-113.5%
2017S-$2.080.62%
2016S-$2.0757.28%
2015S-$1.3225.61%
2014S-$1.0518.84%
2013S-$0.88-1085.71%
2012S$0.08943

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
S$0.97-89.22%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$4.56-49.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$38.18 323.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S$0.96-89.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
S-$2.59-128.79%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$6.17-31.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
S-$9.65-207.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$2.40-73.39%๐Ÿ‡ฌ๐Ÿ‡ง UK